Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

Author： Brandberg Yvonne   Johansson Hemming   Aamdal Steinar   Bastholt Lars   Hernberg Michaela   Stierner Ulrika   von der Maase Hans   Hansson Johan    

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.52, Iss.6, 2013-08, pp. : 1086-1093

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intermediate dose interferon alpha in adjuvant treatment for high-risk melanoma: A single institution's experience

By Tas Faruk   Kurul Sidika   Camlica Hakan   Topuz Erkan  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 471-477

Humana Press, Inc

Access to resources Recommend Favorite

Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain

By Gonzalez-Larriba J.L.   Serrano S.   Alvarez-Mon M.   Camacho F.   Casado M.A.   Daz-Perez J.L.   Daz-Rubio E.   Fosbrook L.   Guillem V.   Lopez-Lopez J.J.   Moreno-Nogueira J.A.   Toribio J.  

European Journal of Cancer, Vol. 36, Iss. 18, 2000-12 ,pp. : 2344-2352

Elsevier

Access to resources Recommend Favorite

A Retrospective Cost-effectiveness Analysis of Interferon as Adjuvant Therapy in High-risk Resected Cutaneous Melanoma

By Messori A.   Becagli P.   Trippoli S.   Tendi E.  

European Journal of Cancer, Vol. 33, Iss. 9, 1997-08 ,pp. : 1373-1379

Elsevier

Access to resources Recommend Favorite

Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial

By Stadler Rudolf   Luger Thomas   Bieber Thomas   Köhler Ulrike   Linse Ruthild   Technau Kristin   Schubert Roland   Schroth Katja   Vakilzadeh Feredoun   Volkenandt Matthias   Gollnick Harald   Von Eick Harald   Thoren Fredrik   Strannegård Örjan  

Acta Oncologica, Vol. 45, Iss. 4, 2006-06 ,pp. : 389-399

Informa Healthcare

Access to resources Recommend Favorite

Regarding Ng et al.: Defining the Role of Adjuvant Radiotherapy for High-Risk Stage I Endometrial Patients - To the Editor

By Petereit D.G.   Frederickson H.  

Gynecologic Oncology, Vol. 82, Iss. 2, 2001-08 ,pp. : 407-408

Elsevier

Access to resources Recommend Favorite